430
Views
2
CrossRef citations to date
0
Altmetric
Original Articles

Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

Pages 107-116 | Received 14 Nov 2017, Accepted 13 Apr 2019, Published online: 05 Jul 2019

References

  • Bender, R., Friede, T., Koch, A., Kuss, O., Schlattmann, P., Schwarzer, G., and Skipka, G. (2018), “Methods for Evidence Synthesis in the Case of Very Few Studies,” Research Synthesis Methods, 9, 382–392.
  • Böhning, D., and Sarol, J. (2000), “Estimating Risk Difference in Multicenter Studies Under Baseline-Risk Heterogeneity,” Biometrics, 56, 304–308. DOI: 10.1111/j.0006-341X.2000.00304.x.
  • Browne, W. J., and Draper, D. (2006), “A Comparison of Bayesian and Likelihood-Based Methods for Fitting Multilevel Models,” Bayesian Analysis, 1, 473–514. DOI: 10.1214/06-BA117.
  • Carpenter, B., Gelman, A., Hoffman, M., Lee, D., Goodrich, B., Betancourt, M., Brubaker, M., Guo, J., Li, P., and Riddell, A. (2017), “Stan: A Probabilistic Programming Language,” Journal of Statistical Software, 76, 1–32. DOI: 10.18637/jss.v076.i01.
  • Carvalho, C. M., Polson, N. G., and Scott, J. G. (2009), “Handling Sparsity via the Horseshoe,” in Proceedings of the Twelfth International Conference on Artificial Intelligence and Statistics, eds. D. van Dyk and M. Welling, Brookline: Microtome Publishing, pp. 73–80.
  • Friede, T., Röver, C., Wandel, S., and Neuenschwander, B. (2017), “Meta-Analysis of Few Small Studies in Orphan Diseases,” Research Synthesis Methods, 8, 79–91. DOI: 10.1002/jrsm.1217.
  • Gelman, A., Carlin, J. B., Stern, H. S., and Rubin, D. B. (2014), Bayesian Data Analysis (3rd ed.), Boca Raton, FL: CRC Press.
  • Grambauer, N., Schumacher, M., Dettenkofer, M., and Beyersmann, J. (2010), “Incidence Densities in a Competing Events Analysis,” American Journal of Epidemiology, 172, 1077–1084. DOI: 10.1093/aje/kwq246.
  • Gravestock, I., and Held, L. (2017), “Adaptive Power Priors With Empirical Bayes for Clinical Trials,” Pharmaceutical Statistics, 16, 349–360. DOI: 10.1002/pst.1814.
  • Guyot, P., Ades, A., Ouwens, M. J., and Welton, N. J. (2012), “Enhanced Secondary Analysis of Survival Data: Reconstructing the Data From Published Kaplan–Meier Survival Curves,” BMC Medical Research Methodology, 12, 9. DOI: 10.1186/1471-2288-12-9.
  • Han, B., Zhan, J., John Zhong, Z., Liu, D., and Lindborg, S. (2017), “Covariate-Adjusted Borrowing of Historical Control Data in Randomized Clinical Trials,” Pharmaceutical Statistics, 16, 296–308. DOI: 10.1002/pst.1815.
  • Higgins, J., and Whitehead, A. (1996), “Borrowing Strength From External Trials in a Meta-Analysis,” Statistics in Medicine, 15, 2733–2749. DOI: 10.1002/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0.
  • Higgins, J. P., and Green, S. (eds.) (2011), “Cochrane Handbook for Systematic Reviews of Interventions, Version 5.1.0 (updated March 2011),” The Cochrane Collaboration, available at http://handbook.cochrane.org.
  • Hobbs, B. P., Carlin, B. P., Mandrekar, S. J., and Sargent, D. J. (2011), “Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials,” Biometrics, 67, 1047–1056. DOI: 10.1111/j.1541-0420.2011.01564.x.
  • Holzhauer, B. (2017), “Meta-Analysis of Aggregate Data on Medical Events,” Statistics in Medicine, 36, 723–737. DOI: 10.1002/sim.7181.
  • Holzhauer, B., and Glimm, E. (2018), “Comments on ‘A Bayesian Meta-Analysis Method for Estimating Risk Difference of Rare Events’,” Journal of Biopharmaceutical Statistics, 28, 1015–1017, PMID: 29902101. DOI: 10.1080/10543406.2018.1485684.
  • Ibrahim, J. G., and Chen, M.-H. (2000), “Power Prior Distributions for Regression Models,” Statistical Science, 15, 46–60. DOI: 10.1214/ss/1009212673.
  • Ibrahim, J. G., Chen, M.-H., Gwon, Y., and Chen, F. (2015), “The Power Prior: Theory and Applications,” Statistics in Medicine, 34, 3724–3749. DOI: 10.1002/sim.6728.
  • Lane, P. W. (2013), “Meta-Analysis of Incidence of Rare Events,” Statistical Methods in Medical Research, 22, 117–132. DOI: 10.1177/0962280211432218.
  • Li, J. X., Chen, W.-C., and Scott, J. A. (2016), “Addressing Prior-Data Conflict With Empirical Meta-Analytic-Predictive Priors in Clinical Studies With Historical Information,” Journal of Biopharmaceutical Statistics, 26, 1056–1066. DOI: 10.1080/10543406.2016.1226324.
  • Lijoi, A. (2003), “Approximating Priors by Finite Mixtures of Conjugate Distributions for an Exponential Family,” Journal of Statistical Planning and Inference, 113, 419–435. DOI: 10.1016/S0167-7152(01)00205-X.
  • Neuenschwander, B., Branson, M., and Spiegelhalter, D. J. (2009), “A Note on the Power Prior,” Statistics in Medicine, 28, 3562–3566. DOI: 10.1002/sim.3722.
  • Neuenschwander, B., Wandel, S., Roychoudhury, S., and Bailey, S. (2016), “Robust Exchangeability Designs for Early Phase Clinical Trials With Multiple Strata,” Pharmaceutical Statistics, 15, 123–134. DOI: 10.1002/pst.1730.
  • Piepho, H.-P., Williams, E., and Madden, L. (2012), “The Use of Two-Way Linear Mixed Models in Multitreatment Meta-Analysis,” Biometrics, 68, 1269–1277. DOI: 10.1111/j.1541-0420.2012.01786.x.
  • Quan, H., Zhang, B., C. Chuang-Stein, Jones, B., and on behalf of the EFSPI Integrated Data Analysis Efficacy Working Group (2017), “Integrated Data Analysis for Assessing Treatment Effect Through Combining Information From All Sources,” Statistics in Biopharmaceutical Research, 9, 52–64. DOI: 10.1080/19466315.2016.1197150.
  • Robert, C. (2007), The Bayesian Choice: From Decision-Theoretic Foundations to Computational Implementation (2nd ed.), New York: Springer.
  • Rothman, K. J., Greenland, S., and Lash, T. L. (2008), Modern Epidemiology (3rd ed.), Philadelphia, PA: Lippincott Williams & Wilkins.
  • Schmidli, H., Gsteiger, S., Roychoudhury, S., O’Hagan, A., Spiegelhalter, D., and Neuenschwander, B. (2014), “Robust Meta-Analytic-Predictive Priors in Clinical Trials With Historical Control Information,” Biometrics, 70, 1023–1032. DOI: 10.1111/biom.12242.
  • Shun, Z., Lei, G., Liu, Q., Zheng, W., Quan, H., and Hitier, S. (2016), “Concepts, Methods, and Practical Considerations of Meta-Analysis in Drug Development,” Statistics in Biopharmaceutical Research, 8, 287–292. DOI: 10.1080/19466315.2016.1174148.
  • Sweeting, M. J., Sutton, A. J., and Lambert, P. C. (2004), “What to Add to Nothing? Use and Avoidance of Continuity Corrections in Meta-Analysis of Sparse Data,” Statistics in Medicine, 23, 1351–1375. DOI: 10.1002/sim.1761.
  • U.S. FDA Center for Devices and Radiological Health (2010), “Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,” available at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071072.htm.
  • Warren, F. C., Abrams, K. R., Golder, S., and Sutton, A. J. (2012), “Systematic Review of Methods Used in Meta-Analyses Where a Primary Outcome Is an Adverse or Unintended Event,” BMC Medical Research Methodology, 12, 64. DOI: 10.1186/1471-2288-12-64.
  • Weaver, J., Ohlssen, D., and Li, J. X. (2016), “Strategies on Using Prior Information When Assessing Adverse Events,” Statistics in Biopharmaceutical Research, 8, 106–115. DOI: 10.1080/19466315.2015.1067252.
  • Williams, D. R., Rast, P., and Bürkner, P. C. (2018), “Bayesian Meta-Analysis With Weakly Informative Prior Distributions,” PsyArXiv, DOI: 10.31234/osf.io/7tbrm.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.